- Home
- CLPT vs CABA Comparison
CLPT vs CABA Comparison
Compare CLPT & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPT | CABA |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.9M | 462.9M |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CLPT | CABA |
|---|---|---|
| Price | $13.70 | $2.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $20.00 | $14.50 |
| AVG Volume (30 Days) | 543.7K | ★ 4.9M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,971,000.00 | N/A |
| Revenue This Year | $45.67 | N/A |
| Revenue Next Year | $19.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.78 | N/A |
| 52 Week Low | $8.27 | $2.00 |
| 52 Week High | $30.10 | $4.23 |
Technical Indicators
Market Signals| Indicator | CLPT | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 38.35 |
| Support Level | $13.42 | $2.02 |
| Resistance Level | $15.29 | $3.41 |
| Average True Range (ATR) | 0.61 | 0.24 |
| MACD | -0.08 | -0.09 |
| Stochastic Oscillator | 25.25 | 4.72 |
Price Performance
Historical ComparisonAbout CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.